Journey MedicalDERM
DERM
About: Journey Medical Corp is a commercial stage pharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company's portfolio includes eight branded and three authorized generic prescription drugs for dermatological conditions that are marketed in the United States. Some of the group's products are Qbrexza, Accutane, Amzeeq, Exelderm and others.
Employees: 58
0
Funds holding %
of 6,809 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
17% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 6
3% more funds holding
Funds holding: 35 [Q2] → 36 (+1) [Q3]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]
2.2% less ownership
Funds ownership: 16.85% [Q2] → 14.64% (-2.2%) [Q3]
8% less capital invested
Capital invested by funds: $13.3M [Q2] → $12.2M (-$1.12M) [Q3]
20% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 10
Research analyst outlook
We haven’t received any recent analyst ratings for DERM.
Financial journalist opinion
Negative
Zacks Investment Research
1 month ago
Journey Medical Corporation (DERM) Reports Q3 Loss, Tops Revenue Estimates
Journey Medical Corporation (DERM) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to earnings of $0.80 per share a year ago.
Neutral
GlobeNewsWire
1 month ago
Journey Medical Corporation Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
U.S. FDA approved Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the treatment of inflammatory lesions of rosacea in adults; launch expected in late Q1 or early Q2 of 2025
Positive
Zacks Investment Research
1 month ago
Journey Medical (DERM) Soars 7.3%: Is Further Upside Left in the Stock?
Journey Medical (DERM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Neutral
GlobeNewsWire
1 month ago
Journey Medical Corporation Announces U.S. FDA Approval of Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea
Journey Medical to host investor conference call on Monday, November 4, 2024, at 8:30 a.m. E.T. Journey Medical to host investor conference call on Monday, November 4, 2024, at 8:30 a.m. E.T.
Neutral
GlobeNewsWire
2 months ago
Journey Medical Corporation Announces DFD-29 Data Presented at 44th Fall Clinical Dermatology Conference
Poster Presented on Dermal and Systemic Pharmacokinetics of Oral DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) versus Oral Doxycycline 40 mg Capsules (Oracea®) in Healthy Subjects
Neutral
GlobeNewsWire
2 months ago
Journey Medical Corporation to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
SCOTTSDALE, Ariz., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that members of Journey Medical's management team will attend one-on-one meetings at the 3rd Annual ROTH Healthcare Opportunities Conference, scheduled to take place on Wednesday, October 9, 2024 in New York City.
Neutral
GlobeNewsWire
3 months ago
Journey Medical Corporation to Participate in the Lake Street Capital Markets 8th Annual Best Ideas Growth (BIG) Conference
SCOTTSDALE, Ariz., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that Claude Maraoui, President and Chief Executive Officer, will attend one-on-one meetings at the Lake Street Capital Markets 8th Annual Best Ideas Growth (BIG) Conference, scheduled to take place on Thursday, September 12, 2024 in New York City.
Neutral
GlobeNewsWire
3 months ago
Journey Medical Corporation to Present at the H.C. Wainwright 26th Annual Global Investment Conference
SCOTTSDALE, Ariz., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that Claude Maraoui, President and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 26th Annual Global Investment Conference. The presentation will be available for on-demand viewing by conference attendees starting on September 9, 2024, at 7:00 a.m. ET. The Company will also attend one-on-one meetings during the conference.
Neutral
Seeking Alpha
4 months ago
Journey Medical Corporation (DERM) Q2 2024 Earnings Call Transcript
Journey Medical Corporation (NASDAQ:DERM ) Q2 2024 Results Conference Call August 12, 2024 4:30 PM ET Company Participants Jaclyn Jaffe - Senior Director, Corporate Operations Claude Maraoui - Co-Founder, President and CEO Joseph Benesch - Chief Financial Officer Srini Sidgiddi - Vice President, Research and Development Ramsey Alloush - General Counsel and Corporate Secretary Conference Call Participants Kalpit Patel - B. Riley Securities Scott Henry - Alliance Global Partners Jason Wittes - Roth Operator Ladies and gentlemen, thank you for standing by.
Negative
Zacks Investment Research
4 months ago
Journey Medical Corporation (DERM) Reports Q2 Loss, Tops Revenue Estimates
Journey Medical Corporation (DERM) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.46 per share a year ago.
Charts implemented using Lightweight Charts™